Sound Income Strategies LLC Buys 315 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sound Income Strategies LLC boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 41.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,077 shares of the company’s stock after acquiring an additional 315 shares during the quarter. Sound Income Strategies LLC’s holdings in Moderna were worth $115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Allworth Financial LP raised its position in Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association lifted its stake in shares of Moderna by 2.3% in the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after acquiring an additional 102 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after acquiring an additional 116 shares during the period. Geo Capital Gestora de Recursos Ltd grew its position in Moderna by 0.4% during the 4th quarter. Geo Capital Gestora de Recursos Ltd now owns 32,339 shares of the company’s stock worth $3,216,000 after acquiring an additional 144 shares during the last quarter. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its position in Moderna by 6.5% in the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock valued at $245,000 after purchasing an additional 151 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00. Following the completion of the sale, the director now owns 2,086,931 shares in the company, valued at $212,199,144.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO James M. Mock sold 705 shares of Moderna stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now directly owns 5,048 shares in the company, valued at $514,542.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00. Following the completion of the transaction, the director now directly owns 2,086,931 shares in the company, valued at approximately $212,199,144.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 396,255 shares of company stock worth $54,210,631. 15.70% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on MRNA. William Blair reissued a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Evercore ISI assumed coverage on Moderna in a report on Tuesday, May 14th. They set an “in-line” rating and a $120.00 price target on the stock. Oppenheimer increased their price objective on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Finally, Royal Bank of Canada upped their target price on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, June 3rd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $129.02.

Moderna Trading Down 11.0 %

Shares of NASDAQ:MRNA traded down $15.15 during midday trading on Wednesday, reaching $122.45. 7,716,528 shares of the company’s stock traded hands, compared to its average volume of 4,205,413. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The stock has a 50 day moving average of $133.02 and a 200 day moving average of $111.32. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the prior year, the business earned $0.19 EPS. The business’s revenue for the quarter was down 91.0% compared to the same quarter last year. On average, research analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.